

Association Between Inherited Germline Mutations in C of Pancreatic Cancer

JAMA - Journal of the American Medical Association
319, 2401

DOI: [10.1001/jama.2018.6228](https://doi.org/10.1001/jama.2018.6228)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Psychological Impact of Learning CDKN2A Variant Status as a Genetic Research Result. <i>Public Health Genomics</i> , 2018, 21, 154-163.	1.0	7
2	Editorial Commentary on “Psychological Impact of Learning CDKN2A Variant Status as a Genetic Research Result” by Zhu et al.. <i>Public Health Genomics</i> , 2018, 21, 164-168.	1.0	0
3	Intercepting Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, 1175-1176.	1.1	1
4	AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , 2018, 11, 735-778.	1.5	36
5	Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Oncology Research and Treatment</i> , 2018, 41, 619-625.	1.2	11
6	Gene Therapy for Pancreatic Diseases: Current Status. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3415.	4.1	11
7	Incidence of Pathogenic Variants in Those With a Family History of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 330.	2.8	4
8	Inherited pancreatic cancer risk. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 454-454.	17.8	0
9	Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Proband’s Susceptibility Gene Mutation Status. <i>Journal of the National Cancer Institute</i> , 2019, 111, 264-271.	6.3	10
10	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. <i>Radiation Oncology</i> , 2019, 14, 141.	2.7	285
11	Screening for Pancreatic Cancer—Is There Hope?. <i>JAMA Internal Medicine</i> , 2019, 179, 1313.	5.1	6
12	Screening for Pancreatic Cancer Gets a D, but the Student Is Improving. <i>JAMA Surgery</i> , 2019, 154, 795.	4.3	8
13	Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort. <i>Clinical Genetics</i> , 2019, 96, 579-584.	2.0	6
14	Germline mutations and their clinical applications in cancer. <i>Breast Cancer Management</i> , 2019, 8, BMT23.	0.2	8
15	Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. <i>Modern Pathology</i> , 2019, 32, 1806-1813.	5.5	21
16	PARP inhibition – opportunities in pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 595-596.	27.6	19
17	Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 651-654.	3.1	6
18	ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1899-1908.	4.1	52

#	ARTICLE	IF	CITATIONS
19	Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. <i>Oncology Reviews</i> , 2019, 13, 430.	1.8	9
20	Health behaviours and beliefs in individuals with familial pancreatic cancer. <i>Familial Cancer</i> , 2019, 18, 457-464.	1.9	4
21	Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 561.	4.1	32
22	Germline <i>BRCA2</i> K3326X and <i>CHEK2</i> I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 145, 686-693.	5.1	20
23	<p>Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3721-3739.	1.9	15
24	Nowadays pancreatic cancer prognosis. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 395-396.	0.2	0
25	Marine natural products in the discovery and development of potential pancreatic cancer therapeutics. <i>Advances in Cancer Research</i> , 2019, 144, 299-314.	5.0	8
26	The Role of <i>BRCA</i> Testing in Hereditary Pancreatic and Prostate Cancer Families. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 79-86.	3.8	73
27	Genetic Counseling and Testing in a Community Setting: Quality, Access, and Efficiency. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e34-e44.	3.8	56
28	Insights into BRCA Cancer Predisposition from Integrated Germline and Somatic Analyses in 7632 Cancers. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz028.	2.9	10
29	Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1238-1245.	2.5	48
30	Evaluating Susceptibility to Pancreatic Cancer: ASCO Clinical Practice Provisional Clinical Opinion Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 108-111.	2.5	15
31	Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result. <i>Genetics in Medicine</i> , 2019, 21, 2468-2477.	2.4	6
32	Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2019, 37, 153-164.	1.6	135
33	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 1305-1315.	1.6	266
34	Genetics of Familial and Sporadic Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 2041-2055.	1.3	52
35	Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. <i>Gastroenterology</i> , 2019, 156, 1905-1913.	1.3	47
36	Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. <i>Journal of Clinical Oncology</i> , 2019, 37, 1070-1080.	1.6	65

#	ARTICLE	IF	CITATIONS
37	Painting a portrait: Analysis of national health survey data for cancer genetic counseling. <i>Cancer Medicine</i> , 2019, 8, 1306-1314.	2.8	12
38	El pronóstico del cáncer de páncreas a día de hoy. <i>Medicina Clínica</i> , 2019, 152, 395-396.	0.6	0
39	Multigene panel testing versus syndrome-specific germline testing for inherited cancer risk: a somewhat different way™. <i>Personalized Medicine</i> , 2019, 16, 83-86.	1.5	1
40	Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. <i>Cancers</i> , 2019, 11, 193.	3.7	12
41	Toward automation of germline variant curation in clinical cancer genetics. <i>Genetics in Medicine</i> , 2019, 21, 2116-2125.	2.4	27
42	Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i> . <i>Cancer Prevention Research</i> , 2019, 12, 599-608.	1.5	6
43	Hereditary Pancreatic Cancer Syndromes: Providing Care to At-Risk Families. <i>Clinical Journal of Oncology Nursing</i> , 2019, 23, 579-582.	0.6	1
44	Palliative chemotherapy in pancreatic cancer—treatment sequences. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 56-56.	3.0	21
45	Germline genetics in localized prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 326-333.	1.8	1
46	Is the Early Detection of Pancreatic Cancer Possible? It Is Good News, Bad News. <i>Pancreas</i> , 2019, 48, 591-593.	1.1	6
47	Next-Generation Sequencing in Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 739-748.	1.1	26
48	Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline <i>BRCA</i> or <i>PALB2</i> Mutation. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	22
49	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 535-546.	1.8	22
50	Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. <i>American Journal of Gastroenterology</i> , 2019, 114, 665-670.	0.4	35
51	Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. <i>Familial Cancer</i> , 2019, 18, 241-251.	1.9	18
52	Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1101-1110.	1.7	55
53	Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing. <i>Journal of Human Genetics</i> , 2020, 65, 125-132.	2.3	6
54	Family history of cancer and subsequent risk of cancer: A large-scale population-based prospective study in Japan. <i>International Journal of Cancer</i> , 2020, 147, 331-337.	5.1	6

#	ARTICLE	IF	CITATIONS
55	A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. <i>Genetics in Medicine</i> , 2020, 22, 407-415.	2.4	136
56	Health Care Provider Perceptions of Caring for Individuals with Inherited Pancreatic Cancer Risk. <i>Journal of Cancer Education</i> , 2020, 35, 194-203.	1.3	3
57	Functional characterization of 84 PALB2 variants of uncertain significance. <i>Genetics in Medicine</i> , 2020, 22, 622-632.	2.4	40
58	ATM-Mutated Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 143-147.	1.1	12
59	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. <i>Gut</i> , 2020, 69, 7-17.	12.1	357
60	MSH6 gene pathogenic variant identified in familial pancreatic cancer in the absence of colon cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 345-349.	1.6	5
61	Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 122, 293-294.	6.4	3
62	Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 721-737.	2.5	21
63	Hepatosplenic $\hat{1}\hat{2}$ T-Cell Lymphoma as Second Malignancy in Young Adult Patient With Previously Undiagnosed Ataxia-Telangiectasia. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e463-e465.	0.6	4
64	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1385-1394.	7.0	31
65	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 130.	17.0	166
66	Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm ₅ Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. <i>Journal of Clinical Oncology</i> , 2020, 38, 4086-4094.	1.6	7
67	Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6505-6512.	7.0	24
68	Germline genetic variability in pancreatic cancer risk and prognosis. <i>Seminars in Cancer Biology</i> , 2022, 79, 105-131.	9.6	30
69	Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. <i>Cancers</i> , 2020, 12, 2774.	3.7	20
70	Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. <i>EBioMedicine</i> , 2020, 60, 103033.	6.1	39
71	Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e1681-e1690.	3.7	5
72	Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 527-535.e14.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 375-403.	329.8	237
74	BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives. <i>Cancers</i> , 2020, 12, 3346.	3.7	13
75	DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns. <i>Frontiers in Pediatrics</i> , 2020, 8, 570084.	1.9	42
76	The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. <i>Modern Pathology</i> , 2020, 33, 2544-2563.	5.5	23
77	Expanding cancer predisposition genes with ultra-rare cancer-exclusive human variations. <i>Scientific Reports</i> , 2020, 10, 13462.	3.3	8
78	Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 586-590.	1.3	5
79	Diabetes, Weight Change, and Pancreatic Cancer Risk. <i>JAMA Oncology</i> , 2020, 6, e202948.	7.1	72
80	Longitudinal Case-Control Studies Using Next-Generation Sequencing (NGS). <i>Clinical OMICs</i> , 2020, 7, 6-7.	0.0	0
81	Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. <i>Genes</i> , 2020, 11, 1098.	2.4	9
82	Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. <i>Gut</i> , 2021, 70, 1894-1903.	12.1	49
83	Early detection of pancreatic cancer. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 456-461.	2.3	19
84	Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3704.	3.7	18
85	Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 3606-3614.	4.1	15
86	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 999-1008.	2.5	19
87	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1213-1221.	6.3	51
88	<p>BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2731-2742.	1.9	69
89	Genetic variants of the peroxisome proliferatorâ€activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer. <i>Molecular Carcinogenesis</i> , 2020, 59, 930-939.	2.7	11
90	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)â€Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. <i>Cancers</i> , 2020, 12, 1158.	3.7	30

#	ARTICLE	IF	CITATIONS
91	From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4067.	4.1	18
92	BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice. <i>Nature Communications</i> , 2020, 11, 3018.	12.8	16
93	Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. <i>Cancer Research</i> , 2020, 80, 3179-3192.	0.9	15
94	Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. <i>Familial Cancer</i> , 2020, 19, 223-239.	1.9	39
95	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1409-1418.	1.6	64
96	Early detection of pancreatic cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 698-710.	8.1	258
97	Resection for pancreatic cancer metastases contributes to survival. <i>Medicine (United States)</i> , 2020, 99, e20564.	1.0	0
98	AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary. <i>Gastroenterology</i> , 2020, 159, 760-764.	1.3	6
99	Case 7-2020: A 52-Year-Old Man with a Mass in the Left Breast. <i>New England Journal of Medicine</i> , 2020, 382, 856-864.	27.0	1
100	<p>Familial Pancreatic Cancer: Current Perspectives</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 743-758.	1.9	29
101	HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 241-250.	2.0	5
102	A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. <i>EBioMedicine</i> , 2020, 53, 102675.	6.1	29
103	Upfront molecular profiling of pancreatic cancer patients â€“ An idea whose time has come. <i>Pancreatology</i> , 2020, 20, 391-393.	1.1	8
104	Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1162-1169.	6.3	114
105	ATM Serine/Threonine Kinase and its Role in Pancreatic Risk. <i>Genes</i> , 2020, 11, 108.	2.4	20
106	Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. <i>Cancer Medicine</i> , 2020, 9, 4004-4013.	2.8	25
107	Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1492-1500.	2.5	5
108	Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic <i>CDKN2A</i> variants. <i>Journal of Medical Genetics</i> , 2021, 58, 264-269.	3.2	13

#	ARTICLE	IF	CITATIONS
109	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1997-2010.	7.0	15
110	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1069-1081.	7.0	75
111	Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 373-384.	2.8	11
112	Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. <i>Cancer Medicine</i> , 2021, 10, 933-943.	2.8	12
113	Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. <i>Surgery</i> , 2021, 169, 629-635.	1.9	2
114	Unique roles of rare variants in the genetics of complex diseases in humans. <i>Journal of Human Genetics</i> , 2021, 66, 11-23.	2.3	74
115	Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants. <i>Familial Cancer</i> , 2021, 20, 97-101.	1.9	3
116	DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. <i>Gut</i> , 2021, 70, 606-617.	12.1	108
117	Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2275-2286.	1.4	4
118	Common Considerations in Male Breast Cancer Survivors. , 2021, , 319-328.		0
119	A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. <i>Journal of Biological Chemistry</i> , 2021, 296, 100634.	3.4	2
120	Hereditary Syndromes and Pancreatic Cancer. , 2021, , 29-49.		0
121	Genetics of Breast and Ovary Cancers Associated with Hereditary Cancers and their Clinical Management. , 2021, 04, .		0
123	Pancreatic Cancer Screening. <i>Clinical Gastroenterology</i> , 2021, , 147-161.	0.0	0
124	Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. <i>Journal of Medical Genetics</i> , 2021, , jmedgenet-2020-107230.	3.2	11
125	Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e236-e247.	2.9	22
126	A Population-Based Study of Genes Previously Implicated in Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 440-451.	27.0	414
127	High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. <i>Clinical Cancer Research</i> , 2021, 27, 2523-2532.	7.0	17

#	ARTICLE	IF	CITATIONS
128	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1725-1741.	6.1	53
129	Familial Pancreatic Intraductal Papillary and Mucinous Neoplasms Do Not Carry Constitutional or Postzygotic GNAS Activating Mutations. <i>Pancreas</i> , 2021, 50, e14-e15.	1.1	1
130	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. <i>Cancer Research</i> , 2021, 81, 3134-3143.	0.9	8
131	Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 19.	1.5	1
132	PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	7
133	Inherited predisposition to pancreatic cancer. <i>Seminars in Oncology</i> , 2021, 48, 2-9.	2.2	0
134	NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641836.	3.7	19
135	CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 21.	1.5	36
137	Susceptibility loci for pancreatic cancer in the Brazilian population. <i>BMC Medical Genomics</i> , 2021, 14, 111.	1.5	2
138	Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 559-564.	2.8	3
139	Genetic Variants in Patients With a Family History of Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 602-606.	1.1	2
141	Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants. <i>JCO Precision Oncology</i> , 2021, 5, 988-1000.	3.0	10
142	Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status. <i>Cancer</i> , 2021, 127, 3310-3324.	4.1	22
143	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer â€” Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	1.6	39
144	Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 493-502.	17.8	370
145	How I Approach Screening for Pancreatic Cancer. <i>American Journal of Gastroenterology</i> , 2021, 116, 1569-1571.	0.4	1
146	<i>BRCA</i> mutated pancreatic cancer: A change is coming. <i>World Journal of Gastroenterology</i> , 2021, 27, 1943-1958.	3.3	42
147	Analysis and Interpretation of the Impact of Missense Variants in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5416.	4.1	28

#	ARTICLE	IF	CITATIONS
148	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. <i>JCO Precision Oncology</i> , 2021, 5, 779-791.	3.0	31
149	Curing pancreatic cancer. <i>Seminars in Cancer Biology</i> , 2021, 76, 232-246.	9.6	22
150	Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021). <i>Journal of Pancreatology</i> , 2021, 4, 49-66.	0.9	7
151	Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e153-e165.	3.8	12
153	First international workshop of the ATM and cancer risk group (4-5 December 2019). <i>Familial Cancer</i> , 2022, 21, 211-227.	1.9	10
154	Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer. <i>Scientific Reports</i> , 2021, 11, 12491.	3.3	1
155	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	2.8	14
156	Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications. <i>Oncologist</i> , 2021, 26, e1526-e1537.	3.7	53
157	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114753.	5.9	15
158	The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2021, 19, 301.	4.4	12
159	A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. <i>Journal of Gastroenterology</i> , 2021, 56, 713-721.	5.1	15
160	BRCA-mutant pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2021, 125, 1321-1332.	6.4	15
161	EUS-based Pancreatic Cancer Surveillance in <i>BRCA1/BRCA2/PALB2/ATM</i> Carriers Without a Family History of Pancreatic Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 1033-1040.	1.5	5
162	Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than <i>BRCA1</i> or <i>BRCA2</i> . <i>Journal of Clinical Oncology</i> , 2021, 39, 2528-2534.	1.6	11
163	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. <i>Frontiers in Genetics</i> , 2021, 12, 693933.	2.3	10
164	Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 938-941.	1.1	1
166	Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the <i>ATM</i> Gene. <i>JAMA Oncology</i> , 2021, 7, 1664.	7.1	39
167	Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients. <i>Cancers</i> , 2021, 13, 4430.	3.7	8

#	ARTICLE	IF	CITATIONS
168	Hereditary pancreatic cancer. International Journal of Clinical Oncology, 2021, 26, 1784-1792.	2.2	17
169	Analysis of the Effect of Robots in the Treatment of Pancreatic Cancer Based on Smart Medicine. Journal of Healthcare Engineering, 2021, 2021, 1-12.	1.9	1
170	Early detection of pancreatic cancer: current state and future opportunities. Current Opinion in Gastroenterology, 2021, 37, 532-538.	2.3	6
171	Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. Journal of Medical Genetics, 2022, 59, 793-800.	3.2	12
172	Implementation of an Embedded <sc>In-Clinic</sc> Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Oncologist, 2021, 26, e1982-e1991.	3.7	10
173	Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma. Annals of Gastroenterological Surgery, 2022, 6, 7-16.	2.4	3
174	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Cancer Treatment Reviews, 2021, 99, 102208.	7.7	4
175	Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2021, 326, 851.	7.4	658
176	m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pancreatic Cancer. Frontiers in Immunology, 2021, 12, 739768.	4.8	9
177	Inherited Pancreatic Cancer Syndromes and High-Risk Screening. Surgical Oncology Clinics of North America, 2021, 30, 773-786.	1.5	16
178	Precision Medicine and Pancreatic Cancer. Surgical Oncology Clinics of North America, 2021, 30, 693-708.	1.5	1
179	Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Letters, 2021, 520, 1-11.	7.2	128
182	Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (<i>ATM</i>) Gene are Associated with High and Moderate Risks for Multiple Cancers. Cancer Prevention Research, 2021, 14, 433-440.	1.5	68
183	The role of PARP inhibitors in <i>BRCA</i> mutated pancreatic cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110148.	3.2	21
184	MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer. Diagnostics, 2021, 11, 84.	2.6	15
185	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	4.9	498
186	Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Cancers, 2021, 13, 198.	3.7	10
187	An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice. JAMA Oncology, 2020, 6, 764.	7.1	35

#	ARTICLE	IF	CITATIONS
188	Genomic Cancer Risk Assessment. , 2020, , 187-207.		1
189	Constitutional Mosaic Epimutations “a hidden cause of cancer?. Cell Stress, 2019, 3, 118-135.	3.2	22
190	Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer. World Journal of Gastroenterology, 2019, 25, 5082-5096.	3.3	10
191	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	4.9	314
192	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	1.5	15
193	Evaluation of a custom QIAseq targeted DNA panel with 164 ancestry informative markers sequenced with the Illumina MiSeq. Scientific Reports, 2021, 11, 21040.	3.3	3
194	Lung cancer is also a hereditary disease. European Respiratory Review, 2021, 30, 210045.	7.1	39
195	A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANPRO. British Journal of Cancer, 2021, 125, 1712-1717.	6.4	4
196	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2021, 39, 3918-3926.	1.6	22
197	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Clinical and Translational Gastroenterology, 2021, 12, e00414.	2.5	17
198	Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?“Response. Cancer Prevention Research, 2021, 14, 975-976.	1.5	1
200	Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World Journal of Gastrointestinal Oncology, 2019, 11, 102-116.	2.0	2
201	The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer. Pancreas, 2021, 50, 1123-1130.	1.1	24
202	Improving Outcomes in Pancreatic Cancer. Oncology & Hematology Review, 2020, 16, 59.	0.2	0
204	Precision Oncology. RSC Detection Science, 2020, , 345-362.	0.0	1
205	The Role of Olaparib in Metastatic Pancreatic Cancer. , 2021, 4, 89-91.		0
206	Genomic alterations in tumor tissue and ctDNA from Chinese pancreatic cancer patients. American Journal of Cancer Research, 2021, 11, 4551-4567.	1.4	1
207	Reducing the Risk of and Screening for Pancreatic Cancer. , 2021, , 1-16.		0

#	ARTICLE	IF	CITATIONS
208	Familial Predisposition and Genetic Risk Factors Associated with Pancreatic Cancer. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2022, 32, 1-12.	1.4	1
209	Lynch Syndrome-Associated Cancers Beyond Colorectal Cancer. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2022, 32, 75-93.	1.4	6
210	The next "sweet spot" for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. <i>Mass Spectrometry Reviews</i> , 2023, 42, 822-843.	5.4	10
211	Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Proband on Concomitant Risk to First-Degree Relatives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 372-381.	2.5	3
212	Endoplasmic stress-inducing variants in <i>CPB1</i> and <i>CPA1</i> and risk of pancreatic cancer: A case-control study and meta-analysis. <i>International Journal of Cancer</i> , 2022, 150, 1123-1133.	5.1	11
213	Diagnostic biomarkers for pancreatic cancer: An update. <i>World Journal of Gastroenterology</i> , 2021, 27, 7862-7865.	3.3	8
214	A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100078.	1.7	0
215	Hereditary pancreatic cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2022, 58-59, 101783.	2.4	14
216	Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance. <i>ELife</i> , 2022, 11, .	6.0	6
217	Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1205.	4.1	13
218	ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 523.	4.1	18
219	Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 1-4.	3.4	5
220	Germline Cancer Risk Profiles of Patients With Young-Onset Colorectal Cancer: Findings From a Prospective Universal Germline Testing and Telegenetics Program. <i>Diseases of the Colon and Rectum</i> , 2023, 66, 531-542.	1.3	4
221	American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 827-854.e3.	1.0	12
222	Pancreatic cancer risk to siblings of probands in bilineal cancer settings. <i>Genetics in Medicine</i> , 2022, 24, 1008-1016.	2.4	4
223	ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 817-826.	1.0	31
224	Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant. <i>Journal of Clinical Gastroenterology</i> , 2023, 57, 317-323.	2.2	3
225	A Pilot Study of Blood-Based Methylation Markers Associated With Pancreatic Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 849839.	2.3	0

#	ARTICLE	IF	CITATIONS
226	Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine, 2022, 77, 103897.	6.1	29
227	Genomic analysis of familial pancreatic cancers and intraductal papillary mucinous neoplasms: A cross-sectional study. Cancer Science, 2022, 113, 1821-1829.	3.9	5
228	Whole genome sequencing identifies rare genetic variants in familial pancreatic cancer patients. Annals of Human Genetics, 2022, , .	0.8	1
229	Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101911.	1.5	5
230	Uncovering variable neoplasms between <sc><i>ATM</i></sc> protein-truncating and common missense variants using 394â€‰%694 <sc>UK</sc> Biobank exomes. Genes Chromosomes and Cancer, 2022, 61, 523-529.	2.8	2
231	SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021). Clinical and Translational Oncology, 2022, 24, 693-702.	2.4	1
232	The age-dependent association of risk factors with pancreatic cancer. Annals of Oncology, 2022, 33, 693-701.	1.2	19
233	Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large <sc>US</sc> health care system. Clinical Genetics, 2022, 101, 324-334.	2.0	6
234	Homologous Recombination Deficiencies and Hereditary Tumors. International Journal of Molecular Sciences, 2022, 23, 348.	4.1	27
235	Male Breast Cancer: From Molecular Genetics to Clinical Management. Cancers, 2022, 14, 2006.	3.7	13
236	Pancreatic Ductal Carcinoma Risk Associated with Hereditary Cancer-Risk Genes. Journal of the National Cancer Institute, 2022, , .	6.3	7
237	Expansion of Cancer Risk Profile for <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. JAMA Oncology, 2022, 8, 871.	7.1	70
238	Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group. Current Oncology Reports, 2022, 24, 843-860.	4.0	6
239	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. Journal of Thoracic Oncology, 2022, 17, 873-889.	1.1	44
240	Implementation of a Video-based Remote Germline Testing for Individuals With Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2022, 163, 316-318.e1.	1.3	0
241	Surgical management of BRCA-mutation carriers: A single institution experience. European Journal of Surgical Oncology, 2022, 48, 1706-1712.	1.0	1
242	Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2022, 12, 860767.	2.8	6
243	S1-Leitlinie: Tumorgenetik â€œ Diagnostik im Kontext maligner Erkrankungen. Medizinische Genetik, 2022, 34, 53-68.	0.2	2

#	ARTICLE	IF	CITATIONS
244	Genetic and chemotherapeutic influences on germline hypermutation. <i>Nature</i> , 2022, 605, 503-508.	27.8	43
245	Anti-Tumor and Anti-Metastasis Effects of Berbamine-Loaded Lipid Nanoparticles on Pancreatic Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 3097-3106.	1.7	5
246	Genetic Susceptibility in Understanding of Pancreatic Ductal Adenocarcinoma Risk: A Decade-Long Effort of the PANDORA Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 942-948.	2.5	0
248	BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. <i>Cancers</i> , 2022, 14, 2453.	3.7	7
250	Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities. <i>Cancers</i> , 2022, 14, 2539.	3.7	5
251	Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. <i>Pancreatology</i> , 2022, 22, 760-769.	1.1	1
252	Endometrial Cancer and BRCA Mutations: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 3114.	2.4	5
253	Identification of high-risk germline variants for the development of pancreatic cancer: Common characteristics and potential guidance to screening guidelines. <i>Pancreatology</i> , 2022, 22, 719-729.	1.1	6
254	PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 403-412.	2.5	1
255	Yeast as a Model to Unravel New BRCA2 Functions in Cell Metabolism. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
256	Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2681-2692.	1.6	18
257	Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review. <i>Kreativna Hirurgija I Onkologija</i> , 2022, 12, 48-55.	0.3	0
258	Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer. <i>Pancreatology</i> , 2022, , .	1.1	0
259	Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	22
260	Founder &BRCA1& mutations in Nepalese population. <i>Journal of Pathology and Translational Medicine</i> , 2022, 56, 212-216.	1.1	2
261	The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. <i>Journal of Clinical Oncology</i> , 2022, 40, 3257-3266.	1.6	69
262	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. <i>Breast</i> , 2022, 65, 32-40.	2.2	25
263	Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. <i>Familial Cancer</i> , 2023, 22, 91-97.	1.9	6

#	ARTICLE	IF	CITATIONS
264	Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. <i>Oncotarget</i> , 2022, 13, 828-841.	1.8	9
265	EARS2 significantly coexpresses with PALB2 in breast and pancreatic cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100595.	1.7	3
266	Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and/or BRCA2 mutation: A systematic review and meta-analysis. <i>Journal of Surgical Oncology</i> , 0, , .	1.7	1
267	Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. <i>Cancers</i> , 2022, 14, 3239.	3.7	11
268	Association of Pathway Mutations With Survival in Taiwanese Breast Cancers. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
269	Hereditary Breast Cancer in the Brazilian State of Ceará (The CHANCE Cohort): Higher-Than-Expected Prevalence of Recurrent Germline Pathogenic Variants. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
270	Building on More Than 20 Years of Progress in Pancreatic Cancer Surveillance for High-Risk Individuals. <i>Journal of Clinical Oncology</i> , 2022, 40, 3230-3234.	1.6	4
271	Heterozygous <i>BRCA1</i> and <i>BRCA2</i> and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1523-1532.	6.3	21
272	Endoplasmic stress-inducing variants in carboxyl ester lipase and pancreatic cancer risk. <i>Pancreatology</i> , 2022, 22, 959-964.	1.1	1
273	The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice. <i>Surgical Pathology Clinics</i> , 2022, , .	1.7	2
274	A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100387.	1.1	1
275	Analyses of rare predisposing variants of lung cancer in 6,004 whole genomes in Chinese. <i>Cancer Cell</i> , 2022, 40, 1223-1239.e6.	16.8	23
276	Reducing the Risk of and Screening for Pancreatic Cancer. , 2022, , 519-533.		0
277	The pathos of precision. <i>New Genetics and Society</i> , 2022, 41, 187-195.	1.2	1
278	Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1681-1688.	6.3	12
279	Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients. <i>Cancers</i> , 2022, 14, 4447.	3.7	5
280	Familial Pancreatic Cancer. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 561-575.	2.2	6
281	Role of genetic testing in hepatic, pancreatic, and biliary cancers. <i>Surgical Oncology</i> , 2022, 44, 101844.	1.6	7

#	ARTICLE	IF	CITATIONS
282	Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2022, 36, 879-895.	2.2	10
283	Contribution of germline PALB2 variants to an unselected and prospectively registered pancreatic cancer patient cohort in Pakistan. Hpb, 2022, , .	0.3	2
284	Risk Factors and Genetic Predisposition. , 2022, , 23-31.		0
285	Pancreatic Cancer Screening. , 2022, , 39-47.		0
286	Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer. ELife, 0, 11, .	6.0	17
287	Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals. Hematology/Oncology Clinics of North America, 2022, 36, 929-942.	2.2	0
288	Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors. Hematology/Oncology Clinics of North America, 2022, 36, 943-960.	2.2	0
290	The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients. Digestive Diseases and Sciences, 0, , .	2.3	0
291	The association of new-onset diabetes with subsequent diagnosis of pancreatic cancerâ€™ novel use of a large administrative database. Journal of Public Health, 0, , .	1.8	0
292	MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications. Translational Oncology, 2023, 27, 101579.	3.7	11
293	Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers. Annals of Surgical Oncology, 2023, 30, 1312-1326.	1.5	4
295	Return of individual genomic research results within the PRAEGNANT multicenter registry study. Breast Cancer Research and Treatment, 0, , .	2.5	0
296	The connection between innervation and metabolic rearrangements in pancreatic cancer through serine. Frontiers in Oncology, 0, 12, .	2.8	0
298	Novel ATM Gene c.5644 C > T (p.Arg1882*) Variant Detected in a Patient with Pancreatic Adenocarcinoma and Two Primary Non-Small Cell Lung Adenocarcinomas: A Case Report. Diseases (Basel, Switzerland), 2022, 10, 115.	2.5	0
299	Inheritance of paternal DNA damage by histone-mediated repair restriction. Nature, 2023, 613, 365-374.	27.8	18
300	Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study. Molecular Medicine, 2023, 29, .	4.4	2
301	Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer. Cancers, 2023, 15, 779.	3.7	4
302	Association of Reported Candidate Monogenic Genes With Lung Cancer Risk. Clinical Lung Cancer, 2023, 24, 313-321.	2.6	4

#	ARTICLE	IF	CITATIONS
303	Dietary Factors and Pancreatic Cancer Risk: An Umbrella Review of Meta-Analyses of Prospective Observational Studies. <i>Advances in Nutrition</i> , 2023, 14, 451-464.	6.4	2
304	Regression of Acoustic Tumor After Chemotherapy for Ovarian Cancer in a Patient With a Breast Cancer Susceptibility Gene 1 (BRCA1) Germline Mutation. <i>Cureus</i> , 2023, , .	0.5	1
305	Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. <i>Gastroenterology</i> , 2023, 164, 752-765.	1.3	17
306	Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2023, 55, 1303-1312.	3.0	1
307	Hereditary cancer syndromes. <i>World Journal of Clinical Oncology</i> , 0, 14, 40-68.	2.3	8
308	FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
309	A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing. <i>ESMO Open</i> , 2023, 8, 100881.	4.5	4
312	Single-cell and bulk RNA sequencing identifies T cell marker genes score to predict the prognosis of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
313	Rare germline variants in pancreatic cancer and multiple primary cancers: an autopsy study. <i>European Journal of Cancer Prevention</i> , 2023, 32, 286-297.	1.3	2
314	Personalized Systemic Therapies in Hereditary Cancer Syndromes. <i>Genes</i> , 2023, 14, 684.	2.4	4
315	Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment. <i>Oncologist</i> , 2023, 28, 486-493.	3.7	0
316	Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases: Workshop Proceedings. <i>Diabetes</i> , 2023, 72, 433-448.	0.6	2
317	Pancreatic cancer cluster region identified in <i>BRCA2</i> . <i>Journal of Medical Genetics</i> , 2023, 60, 1052-1056.	3.2	1
318	Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing. <i>Molecular Genetics & Genomic Medicine</i> , 2023, 11, .	1.2	3
319	Applying Unique Molecular Indices with an Extensive All-in-One Forensic SNP Panel for Improved Genotype Accuracy and Sensitivity. <i>Genes</i> , 2023, 14, 818.	2.4	1
320	Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications. <i>Cancer Medicine</i> , 2023, 12, 11672-11685.	2.8	5
321	Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. <i>Biomedicines</i> , 2023, 11, 1069.	3.2	1
322	Prevalence of a BRCA2 Pathogenic Variant in Hereditary-Breast-and-Ovarian-Cancer-Syndrome Families with Increased Risk of Pancreatic Cancer in a Restricted Italian Area. <i>Cancers</i> , 2023, 15, 2132.	3.7	1

#	ARTICLE	IF	CITATIONS
323	Precision Medicine in Pancreatitis: The Future of Acute Pancreatitis Care. <i>Function</i> , 2023, 4, .	2.3	2
324	Management of Patients With Pancreatic Cancer Using the “Right Track” Model. <i>Oncologist</i> , 2023, 28, 584-595.	3.7	3
325	Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases. <i>Pancreas</i> , 2022, 51, 1061-1073.	1.1	3
326	Integrated In Silico Analysis of Proteogenomic and Drug Targets for Pancreatic Cancer Survival. <i>Methods in Molecular Biology</i> , 2023, , 273-282.	0.9	0
327	Screening for pancreatic cancer has the potential to save lives, but is it practical?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2023, 17, 555-574.	3.0	3
328	Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review. <i>BJS Open</i> , 2023, 7, .	1.7	7
329	Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCA1 and p53. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188914.	7.4	2
330	Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants. <i>JAMA Oncology</i> , 2023, 9, 955.	7.1	2
331	Transforming Diagnosis and Therapeutics Using Cancer Genomics. <i>Cancer Treatment and Research</i> , 2023, , 15-47.	0.5	1
333	Somatic loss of ATM is a late event in pancreatic tumorigenesis. <i>Journal of Pathology</i> , 2023, 260, 455-464.	4.5	2
334	Pancreatic Adenocarcinoma and Ageing: Understanding the Menace for Better Management. <i>Journal of Pancreatology</i> , 0, Publish Ahead of Print, .	0.9	0
335	The role of molecular testing in pancreatic cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482311714.	3.2	4
336	Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes. <i>Human Molecular Genetics</i> , 2023, 32, 2646-2655.	2.9	2
337	Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing for Modern Oncology Diagnosis, Interception, and Therapeutic Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2023, , .	3.8	3
338	Germline mutations in the PALB2 and CHEK2 genes and hereditary cancer. , 2023, 22, 126-136.	0.2	1
339	Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance. <i>Cancer and Metastasis Reviews</i> , 0, , .	5.9	6
340	Genome-scale CRISPR-Cas9 screening stratifies pancreatic cancer with distinct outcomes and immunotherapeutic efficacy. <i>Cellular Signalling</i> , 2023, , 110811.	3.6	0
341	Heterozygous Pathogenic Nonsense Variant in the ATM Gene in a Family with Unusually High Gastric Cancer Susceptibility. <i>Biomedicines</i> , 2023, 11, 2062.	3.2	0

#	ARTICLE	IF	CITATIONS
343	It Is All in the Genes: A Story of Unexpected Survival in a 67-Year-Old Male with Metastatic Pancreatic Cancer. Case Reports in Oncological Medicine, 2023, 2023, 1-4.	0.3	0
346	Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma. JAMA Network Open, 2023, 6, e2327351.	5.9	2
347	BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis. BMC Cancer, 2023, 23, .	2.6	1
348	Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular. Cancer Letters, 2023, 574, 216391.	7.2	2
349	Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. Journal of Translational Medicine, 2023, 21, .	4.4	0
351	Exploiting the molecular subtypes and genetic landscape in pancreatic cancer: the quest to find effective drugs. Frontiers in Genetics, 0, 14, .	2.3	0
352	Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes. Clinica Chimica Acta, 2023, 551, 117567.	1.1	0
353	Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan. Pancreatology, 2023, , .	1.1	0
354	Prevalence of BRCA1 and BRCA2 germline variants in an unselected pancreatic cancer patient cohort in Pakistan. Hereditary Cancer in Clinical Practice, 2023, 21, .	1.5	0
355	A journey to and with the stars: The pancreatic stellate cell story. Pancreatology, 2023, 23, 893-899.	1.1	0
356	Targeted Therapies for Pancreatic Cancer. , 2023, , 67-95.		0
357	Current status and perspectives of genetic testing in gastrointestinal cancer (Review). Oncology Letters, 2023, 27, .	1.8	0
358	Evaluating implementation of NCCN guideline-directed genetic screening recommendations for patients with pancreatic ductal adenocarcinoma. Cancer Causes and Control, 0, , .	1.8	0
359	Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations. JCO Oncology Practice, 2024, 20, 278-290.	2.9	0
362	Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review. Cancers, 2024, 16, 56.	3.7	0
363	Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer. Clinical and Translational Gastroenterology, 2024, 15, e00668.	2.5	0
364	Pan-cancer analysis of the spectrum of homologous recombination DNA repair (HRR) pathway genes in the Indian population: A retrospective observational study. Cancer Research Statistics and Treatment, 2023, 6, 512-525.	0.6	2
365	Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges. Frontiers of Medicine, 2023, 17, 1135-1169.	3.4	0

#	ARTICLE	IF	CITATIONS
367	Heterogeneities in Hereditary Cancer Genes as Revealed by a Large-Scale Genome Analysis. , 2023, , 59-78.		0
370	A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study. Gastroenterology, 2024, 166, 872-885.e2.	1.3	0
371	Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health. Oncotarget, 2024, 15, 134-141.	1.8	0
372	Next-generation therapies for pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2024, 18, 55-72.	3.0	0
374	Upper Gastrointestinal Cancers and the Role of Genetic Testing. Hematology/Oncology Clinics of North America, 2024, 38, 677-691.	2.2	0
375	The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance in high-risk individuals. Familial Cancer, 0, , .	1.9	0